Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD

In this study (n=1094), the addition of oxaliplatin to preoperative capecitabine-based chemoradiation and adjuvant chemotherapy did not improve disease-free survival (3-year rate: 75.8% v 76.5% in the control arm), and was associated with a higher rate of adverse events.

Journal of Clinical Oncology